Unsaponifiable Lipid

Avocado/Soybean Unsaponifiables

Persea americana and Glycine max unsaponifiables

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

300-600 mg/day

watchEffect Window

8-24 weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Avocado-soybean unsaponifiables (ASU) are used for osteoarthritis symptom support, with modest benefit and slow onset in some trials.

Meta analyses for glucosamine, chondroitin, collagen, and ASU show small to moderate improvements in pain and function in some osteoarthritis populations, with heterogeneity by product quality. MSM and hyaluronic acid show modest symptom benefits in some trials. Minority research explores reduced cartilage turnover biomarkers and improved tendon recovery, with limited confirmation.

Lipid-derived unsaponifiable fraction with possible inflammatory and cartilage-supportive effects in OA contexts. Evidence is moderate and condition-specific.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Modest OA pain and stiffness improvement
  • No validated cognition/performance benefit

Secondary Outcomes

  • Joint function trend
  • NSAID-sparing in selected users

Safety

Contraindications and Interactions

Contraindications

  • Soy allergy
  • Severe hepatic comorbidity
  • Pregnancy/lactation (without clinician direction)

Side effects

  • GI discomfort
  • Mild nausea
  • Allergic reaction

Interactions

  • Anticoagulants
  • Anti-inflammatory medications
  • Other joint-support compounds

Avoid if

  • Known soy intolerance
  • Acute inflammatory flares
  • Unknown product quality

Evidence

Study-level References

avocadosoybean-unsaponifiables-SRC-001RCT and controlled supplementation studies.

Randomized and observational osteoarthritis trials of avocado-soybean unsaponifiables.

Population: Adults with knee osteoarthritis.

Dose protocol: ASU 300 mg BID and comparable dosing regimes.

Key findings: Modest benefit in pain and stiffness in some trials.

Notes: Endpoint heterogeneity and potential sponsor or formulary bias.

Paper content

Modest benefit in pain and stiffness in some trials.

avocadosoybean-unsaponifiables-SRC-002Meta-analysis and systematic synthesis.

Reviews comparing ASU against standard OA therapies.

Population: OA cohorts with varying severity.

Dose protocol: Standardized ASU and blended formulations.

Key findings: Moderate confidence for adjunct relief. Limited certainty for broader use.

Notes: Limited high-powered, long-duration standardized trials.

Paper content

Moderate confidence for adjunct relief; limited certainty for broader use.

avocadosoybean-unsaponifiables-SRC-003Systematic review and meta-analysis of randomized placebo-controlled trials
Sourceopen_in_new

Simental-Mendia M, Sanchez-Garcia A, Acosta-Olivo CA, Vilchez-Cavazos F, Osuna-Garate J, Pena-Martinez VM, Simental-Mendia LE. Efficacy and safety of avocado-soybean unsaponifiables for the treatment of hip and knee osteoarthritis: A systematic review and meta-analysis of randomized placebo-controlled trials. Int J Rheum Dis. 2019;22(9):1607-1615. doi:10.1111/1756-185X.13658. PMID:31328413.

Population: Adults with hip or knee osteoarthritis across multiple pooled RCTs.

Dose protocol: ASU 300 mg/day versus placebo across pooled RCTs for hip and knee OA.

Key findings: Meta-analysis found significant pain reduction in knee OA (VAS WMD -17.36 mm, P < 0.0001) and improved Lequesne index (WMD -2.33, P < 0.00001). Hip OA did not show significant benefit. Safety was comparable to placebo.

Notes: The most comprehensive meta-analysis of ASU for OA to date. Confirms that the benefit is strongest for knee OA and weaker or absent for hip OA.

Paper content

This meta-analysis pooled randomized placebo-controlled trials of ASU for hip and knee osteoarthritis. ASU produced a statistically significant reduction in pain by VAS (WMD -9.64 mm) and a clear benefit for knee OA specifically (WMD -17.36 mm for pain, WMD -2.33 for Lequesne index). Hip OA did not show significant benefit. The safety profile was equivalent to placebo with no excess adverse events.

Guides

Setup

Help